{"analyses":[{"ciLowerLimit":"0.39","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.46","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Odds Ratio (OR)","paramValue":"0.76"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"36.3","upperLimit":"59.8","value":"48.0"},{"groupId":"OG001","lowerLimit":"42.7","upperLimit":"66.8","value":"54.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"71"}],"units":"Participants"}],"description":"The percentage of randomized participants who achieved a best overall response (BOR) of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) using International Myeloma Working Group (IMWG) criteria.\n\nsCR= Complete response as defined below plus normal FLC ratio and absence of clonal cells in bone marrow biopsy by immunohistochemistry.\n\nCR = Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \\< 5% plasma cells in bone marrow aspirates.\n\nVGPR = Serum and urine M-protein detectable by immunofixation but not on electrophoresis or \\>/= 90% reduction in serum M-protein plus urine M-protein level \\< 100 mg per 24 h.\n\nPR = \\>/= 50% reduction of serum M-protein plus reduction in 24 h urinary M-protein by \\>/= 90% or to \\< 200 mg per 24 h.","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab:\n\n* Cycles 1 through 4: 240 mg IV Days 1, 15 of each 28-day cycle.\n* Cycles 5 and beyond: 480 mg IV Day 1 of each 28-day cycle.\n\nPomalidomide:\n\n\\- 4 mg PO QD Days 1-21 of each 28-day cycle.\n\nDexamethasone:\n\n* Participants \\</= 75 years old: 40 mg PO Days (1, 8, 15, and 22) of each cycle\n* Participants \\> 75 years old: 20 mg PO Days (1, 8, 15, and 22) of each cycle.","id":"OG000","title":"Arm A: N-Pd"},{"description":"Pomalidomide:\n\n\\- 4 mg PO QD Days 1-21 of each 28-day cycle.\n\nDexamethasone:\n\n* Participants \\</= 75 years old: 40 mg PO Days (1, 8, 15, and 22) of each cycle\n* Participants \\> 75 years old: 20 mg PO Days (1, 8, 15, and 22) of each cycle.","id":"OG001","title":"Arm B: Pd"}],"paramType":"NUMBER","populationDescription":"All randomized participants in Arm A and B. Data was pre-specified to be collected only in the N-Pd and Pd arms.","reportingStatus":"POSTED","timeFrame":"From randomization up to approximately 64 months","title":"Objective Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}